Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28259637 | 0.86 | LPAR3 (0.37) | MEN1KMT2A | |
| SCHEMBL28666575 | 0.85 | LPAR3 (0.42) | MEN1KMT2AESR1ESR2CHRM2 | |
| Phosphoric Acid SCHEMBL28675446 | 0.80 | LPAR3 (0.38) | MEN1KMT2AESR1ESR2CHRM2 | |
| SCHEMBL27256342 | 0.77 | LPAR3 (0.42) | MEN1KMT2AESR1ESR2CHRM2 | |
| SCHEMBL175957 | 0.76 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2784094 | 0.76 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2483954 | 0.76 | CA12 (0.40) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1075365 | 0.76 | CA12 (0.40) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL28992249 | 0.73 | CHRM2 (0.34) | MEN1KMT2AESR1ESR2CHRM2 | |
| SCHEMBL4454861 | 0.71 | MEN1 (0.34) | MEN1KMT2AESR1ESR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108970543-B | Method for inhibiting corrosion and method for oxidizing feed | 通用原子公司 | 2021-11-23 | — | — | CN | disclosed |
| US-10688464-B2 | Corrosion inhibition in hydrothermal processing | GENERAL ATOMICS (US) | 2020-06-23 | — | — | US | disclosed |
| US-20180345241-A1 | CORROSION INHIBITION IN HYDROTHERMAL PROCESSING | BANK OF THE WEST | 2018-12-06 | — | — | US | disclosed |
| US-8097343-B2 | Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents | TRITON SYSTEMS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2035032-A2 | METHODS FOR ESTER DETOXICATION | Human Biomolecular Research Institute (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7384626-B2 | Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents | TRITON SYSTEMS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007146003-A2 | METHODS FOR ESTER DETOXICATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146003-A2 | METHODS FOR ESTER DETOXICATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070286846-A1 | Novel methods for ester detoxication | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2007-12-13 | — | — | US | disclosed |
| US-20070286846-A1 | Novel methods for ester detoxication | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2007-12-13 | — | — | US | disclosed |
| US-20070286846-A1 | Novel methods for ester detoxication | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2007-12-13 | — | — | US | disclosed |
| US-20070071713-A1 | FUNCTIONALIZED DENDRITIC POLYMERS FOR THE CAPTURE AND NEUTRALIZATION OF BIOLOGICAL AND CHEMICAL AGENTS | TRITON SYSTEMS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070014754-A1 | Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents | TRITON SYSTEMS, INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006135406-A2 | FUNCTIONALIZED DENDRITIC POLYMERS FOR THE CAPTURE AND NEUTRALIZATION OF BIOLOGICAL AND CHEMICAL AGENTS | TRITON SYSTEMS, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070071713-A1 | FUNCTIONALIZED DENDRITIC POLYMERS FOR THE CAPTURE AND NEUTRALIZATION OF BIOLOGICAL AND CHEMICAL AGENTS | CD47, CD209, HAVCR2 | MEN1 2208/4885KMT2A 1665/4885ESR1 4579/4885 |
| US-20070286846-A1 | Novel methods for ester detoxication | CES2, BCHE, ACHE | MEN1 4804/4885KMT2A 2377/4885ESR1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.